The Rising Importance of Custom Antibody Generation for Biotherapeutics

As biotherapeutics continues to evolve, the development of more specific and targeted treatments has become a primary focus. This shift has led to a decrease in the use of commercial antibodies as therapeutic reagents and an increase in the generation of custom antibodies tailored to specific biotherapeutics.

Biotherapeutics, also known as biological therapies, involve using living organisms, their derivatives, or various recombinant products to treat or prevent diseases. These therapies have revolutionized the treatment of many severe and chronic diseases, offering new hope to patients worldwide.

Commercial antibodies were commonly used as reagents in the early days of biotherapeutics. These antibodies, produced on a large scale and widely available, played a crucial role in developing and producing biotherapeutic drugs.

As biotherapeutics increase in complexity, Commercial Antibodies have some fundamental limitations.

• One of the main issues is their lack of specificity.
  • Commercial antibodies are designed to target a broad range of antigens, which can lead to off-target effects and reduced therapeutic efficacy.
• Commercial antibodies can lead to batch-to-batch variability, affecting the consistency and reliability of biotherapeutic products.
  • This variability can pose significant challenges in the drug development process, particularly during the stages of clinical trials and regulatory approval.

To overcome these limitations, the field is moving towards custom antibodies. These antibodies are designed and produced to target a specific antigen, increasing the specificity and efficacy of the biotherapeutic.

• Custom antibodies can be generated using various methods, including phage display, hybridoma technology, and single B cell cloning.
• These techniques allow the selection of antibodies with high affinity and specificity for the target antigen, reducing off-target effects and improving therapeutic outcomes.
• This opens the opportunity to generate antibodies from species other than mammalian (IgGs). Antibodies from genetically diverse species like avian (IgYs) can provide unique epitopes to which normal IgG antibodies would not bind. This is also giving rise to chimeric antibodies.
• Using custom antibodies allows for greater control over the production process, reducing batch-to-batch variability and ensuring the consistency of the biotherapeutic product.
  • In the case of IgYs from the avian species, the antibodies are derived from the eggs and provide a significant amount of antibody titers. It is not surprising that IgY use as a reagent has increased significantly over the past five years.

In summary, the shift from commercial antibodies to custom antibodies represents a significant advancement in biotherapeutics. As we continue to develop more specific and targeted treatments, the importance of custom antibodies will only continue to grow. By embracing this shift, we can improve the efficacy and safety of biotherapeutic drugs, offering new hope to patients worldwide.